V
ALXN

Veritable’s Alexion Pharmaceuticals ALXN Stock Holding History

Veritable’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,927
Closed -$354K – 920
2021
Q2 		$354K Buy
1,927
+92
+5% +$15.8K 0.01% 634
2021
Q1 		$281K Sell
1,835
-836
-31% -$129K ﹤0.01% 680
2020
Q4 		$417K Sell
2,671
-878
-25% -$113K 0.01% 543
2020
Q3 		$406K Sell
3,549
-263
-7% -$28.4K 0.01% 507
2020
Q2 		$428K Buy
3,812
+240
+7% +$25.5K 0.01% 500
2020
Q1 		$321K Sell
3,572
-1,065
-23% -$105K 0.01% 546
2019
Q4 		$501K Sell
4,637
-518
-10% -$55.4K 0.01% 527
2019
Q3 		$505K Sell
5,155
-9
-0.2% -$1.01K 0.01% 510
2019
Q2 		$676K Buy
5,164
+712
+16% +$91.8K 0.01% 432
2019
Q1 		$602K Buy
4,452
+181
+4% +$22.5K 0.01% 455
2018
Q4 		$416K Sell
4,271
-1,094
-20% -$129K 0.01% 508
2018
Q3 		$746K Sell
5,365
-124
-2% -$15.6K 0.02% 408
2018
Q2 		$681K Buy
5,489
+951
+21% +$111K 0.01% 432
2018
Q1 		$506K Buy
4,538
+1,170
+35% +$140K 0.01% 498
2017
Q4 		$403K Sell
3,368
-1,030
-23% -$125K 0.01% 558
2017
Q3 		$617K Buy
4,398
+555
+14% +$75.4K 0.01% 459
2017
Q2 		$468K Sell
3,843
-1,762
-31% -$205K 0.01% 527
2017
Q1 		$680K Buy
5,605
+462
+9% +$59.6K 0.02% 416
2016
Q4 		$629K Buy
5,143
+796
+18% +$97.4K 0.02% 415
2016
Q3 		$533K Buy
4,347
+202
+5% +$26K 0.01% 452
2016
Q2 		$484K Sell
4,145
-242
-6% -$34.3K 0.01% 462
2016
Q1 		$611K Sell
4,387
-204
-4% -$30K 0.02% 391
2015
Q4 		$876K Buy
4,591
+835
+22% +$146K 0.02% 343
2015
Q3 		$587K Buy
3,756
+256
+7% +$46.7K 0.02% 406
2015
Q2 		$633K Sell
3,500
-25,938
-88% -$4.48M 0.02% 406
2015
Q1 		$5.1M Buy
29,438
+27
+0.1% +$4.89K 0.11% 146
2014
Q4 		$5.44M Sell
29,411
-633
-2% -$117K 0.11% 145
2014
Q3 		$4.98M Buy
30,044
+19,391
+182% +$3.18M 0.11% 143
2014
Q2 		$1.67M Buy
10,653
+181
+2% +$28.6K 0.03% 289
2014
Q1 		$1.59M Sell
10,472
-1,626
-13% -$259K 0.03% 293
2013
Q4 		$1.61M Buy
12,098
+253
+2% +$30.4K 0.04% 284
2013
Q3 		$1.38M Buy
11,845
+2,115
+22% +$232K 0.03% 315
2013
Q2 		$897K Buy
+9,730
New +$938K 0.02% 426

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return